InnoPharmax
About
About Us
Organization
Our History
News
News
R&D
Pipeline
Anti-infection Agents
Contrast Agents
Oncology Agents
Immunological Agents
Drugs for Rare Diseases
Active Pharmaceutical Ingredient
Products
GemOral
N11005
Technologies
OralPAS®
OralPAS Pro®
MUCR™
Investors
Financial Information
Company Profile
Monthly Revenue
Financial Statements
Corporate Governance
Board Meeting
Committee
Internal Audit
Rule of Procedure
Corporate Social Responsibility
Shareholders Services
Annual Reports
Shareholders' Meetings
Announcements
Contact
Contacts
Contact Information
Career Opportunities
ZH-TW
News
News
News
>
News
>
home
News
All
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
1
2
3
4
5
6
下一頁 >
2022/08/29
InnoPharmax have signed supplementary agreement with Shandong New Times Pharmaceuticals for Sapropterin Dihydrochloride.
2022/03/29
Patent of “Oral Administration of Unstable or Poorly-Absorbed Drugs (N11005)” was granted in U.S.
2022/02/10
First-Patient-In (FPI) of N11005-Oral Insulin Investigator-Initiated-Trial (IIT).
2022/01/18
InnoPharmax have entered supply contract with Astellas in Germany for the Bendamustine.
2021/12/23
InnoPharmax is invited to participate in the online corporate presentation held by Yuan Fu Securities..
2021/12/07
InnoPharmax have signed contract with Ainos Inc. for the development and distribution of oral antiviral treatment.
2021/10/04
D07001 (GemOral) Phase II/III clinical trial in humans for advanced bile duct cancer (Project No. INNO-GO-05) has been approved
2021/09/29
Investigator-Initiated-Trial (IIT) of N11005-Oral insulin formulation is under reviewed by IRB at Gan Nan Hospital.
2021/08/11
API (code: Innopharmax) was approved by the Ministry of Health and Welfare of Taiwan for the drug license.
2021/07/26
Guangzhou Pharmaceuticals has joined the contract between InnoPharmax and North & South Brothers for the oral insulin project.
1
2
3
4
5
6
下一頁 >
uGear Design
-
Website Info.